ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
0,00%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,745
0,14%
Bitcoin
59 362,77
0,41%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Medicinova Inc (MNOV)

  7. Medicinova Inc (MNOV) Actualités

MNOV Medicinova Inc

1,38
0,09 (6,98%)
03 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Medicinova Inc MNOV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,09 6,98% 1,38 00:36:14
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,29 1,29 1,38 1,38 1,29
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
03/4/202401:00GLOBEMediciNova Announces Abstract Regarding Results of a..
27/3/202400:00GLOBEMediciNova Receives a Notice of Allowance for a New Patent..
21/3/202400:00GLOBEMediciNova Announces Two Abstracts regarding MN-001..
12/3/202411:30GLOBEMediciNova Announces New Data and Results of MN-166..
15/2/202422:25EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
19/1/202422:27EDGAR2Form S-8 POS - Securities to be offered to employees in..
19/1/202422:25EDGAR2Form S-8 POS - Securities to be offered to employees in..
19/1/202422:23EDGAR2Form S-8 POS - Securities to be offered to employees in..
19/1/202422:21EDGAR2Form S-8 POS - Securities to be offered to employees in..
17/1/202412:00GLOBEMediciNova Receives a Notice of Grant for a New Patent..
11/1/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202422:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/1/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202300:00GLOBEMediciNova Announces Abstract Regarding MN-166 (ibudilast)..
07/12/202300:00GLOBEMediciNova Receives a Notice of Decision to Grant for a New..
20/11/202313:42IHMARKETNEWSStocks Set to Open Higher as Investors Await FOMC Minutes..
20/11/202300:00GLOBEMediciNova Announces New Data and Results of a Phase 2..
09/11/202322:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
27/10/202307:00GLOBEMediciNova’s Collaborator Initiates Clinical Development of..
11/10/202301:00GLOBEMediciNova Receives a Notice of Allowance for a New Patent..
05/10/202301:00GLOBEMediciNova Receives Gene Therapy Milestone Payment
28/9/202301:00GLOBEMediciNova Announces Results of Studies under BARDA Contract..
18/8/202301:00GLOBEMediciNova Announces Abstract Regarding MN-166 (ibudilast)..
17/8/202301:00GLOBEMediciNova Receives a Notice of Intention to Grant for a New..
16/8/202301:00GLOBEMediciNova Receives a New Patent Covering MN-001 for the..
15/8/202301:00GLOBEMediciNova Receives a Notice of Intention to Grant for a New..
09/8/202322:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202322:17EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/8/202322:05EDGAR2Form 8-K - Current report
29/6/202312:00GLOBEMediciNova Announces Presentation of Results from the Phase..
15/5/202301:00GLOBEMediciNova Receives a Notice of Intention to Grant for a New..

Dernières Valeurs Consultées

NASDAQ
MNOV
Medicinova
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés